Clinical Trial Update: GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol [Phase 2]

View source ↗

Summary

Phase 2 trial update for GW501516 in individuals with low HDL cholesterol has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• GW501516 (GW501516)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Dyslipidaemias, Dyslipidaemia | Phase 2 | Status: COMPLETED